Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Biol Chem ; 291(7): 3209-23, 2016 Feb 12.
Article in English | MEDLINE | ID: mdl-26655716

ABSTRACT

The epithelial cells of the gut form a physical barrier against the luminal contents. The collapse of this barrier causes inflammation, and its therapeutic restoration can protect the gut against inflammation. EGF enhances mucosal barrier function and increases colonocyte proliferation, thereby ameliorating inflammatory responses in the gut. Based on our previous finding that the insect peptide CopA3 promotes neuronal growth, we herein tested whether CopA3 could increase the cell proliferation of colonocytes, enhance mucosal barrier function, and ameliorate gut inflammation. Our results revealed that CopA3 significantly increased epithelial cell proliferation in mouse colonic crypts and also enhanced colonic epithelial barrier function. Moreover, CopA3 treatment ameliorated Clostridium difficile toxin As-induced inflammation responses in the mouse small intestine (acute enteritis) and completely blocked inflammatory responses and subsequent lethality in the dextran sulfate sodium-induced mouse model of chronic colitis. The marked CopA3-induced increase of colonocyte proliferation was found to require rapid protein degradation of p21(Cip1/Waf1), and an in vitro ubiquitination assay revealed that CopA3 directly facilitated ubiquitin ligase activity against p21(Cip1/Waf1). Taken together, our findings indicate that the insect peptide CopA3 prevents gut inflammation by increasing epithelial cell proliferation and mucosal barrier function.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antimicrobial Cationic Peptides/therapeutic use , Coleoptera/metabolism , Colitis/prevention & control , Enteritis/prevention & control , Gastrointestinal Agents/therapeutic use , Insect Proteins/therapeutic use , Intestinal Mucosa/drug effects , Animals , Animals, Outbred Strains , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antimicrobial Cationic Peptides/pharmacology , Cell Proliferation/drug effects , Colitis/immunology , Colitis/metabolism , Colitis/pathology , Colon/drug effects , Colon/immunology , Colon/metabolism , Colon/pathology , Cyclin-Dependent Kinase Inhibitor p21/antagonists & inhibitors , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Enteritis/immunology , Enteritis/metabolism , Enteritis/pathology , Gastrointestinal Agents/pharmacology , HT29 Cells , Humans , Insect Proteins/pharmacology , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Intestine, Small/drug effects , Intestine, Small/immunology , Intestine, Small/metabolism , Intestine, Small/pathology , Male , Mice, Inbred C57BL , Permeability/drug effects , RNA Interference , Tissue Culture Techniques , Ubiquitin-Protein Ligases/chemistry , Ubiquitin-Protein Ligases/genetics , Ubiquitin-Protein Ligases/metabolism , Ubiquitination/drug effects
2.
Biochem Biophys Res Commun ; 448(3): 292-7, 2014 Jun 06.
Article in English | MEDLINE | ID: mdl-24796676

ABSTRACT

We recently isolated a polypeptide from the earthworm Lumbricus terrestris that is structurally similar to defensin, a well-known antibacterial peptide. An 11-mer antibacterial peptide (NH2-RNRRWCIDQQA), designated Lumbricusin, was synthesized based on the amino acid sequence of the isolated polypeptide. Since we previously reported that CopA3, a dung beetle peptide, enhanced neuronal cell proliferation, we here examined whether Lumbricusin exerted neurotropic and/or neuroprotective effects. Lumbricusin treatment induced a time-dependent increase (∼51%) in the proliferation of human neuroblastoma SH-SY5Y cells. Lumbricusin also significantly inhibited the apoptosis and decreased viability induced by treatment with 6-hydroxy dopamine, a Parkinson's disease-mimicking agent. Immunoblot analyses revealed that Lumbricusin treatment increased ubiquitination of p27(Kip1) protein, a negative regulator of cell-cycle progression, in SH-SY5Y cells, and markedly promoted its degradation. Notably, adenoviral-mediated over-expression of p27(Kip1) significantly blocked the antiapoptotic effect of Lumbricusin in 6-hydroxy dopamine-treated SH-SY5Y cells. These results suggest that promotion of p27(Kip1) degradation may be the main mechanism underlying the neuroprotective and neurotropic effects of Lumbricusin.


Subject(s)
Antimicrobial Cationic Peptides/isolation & purification , Helminth Proteins/isolation & purification , Neuroprotective Agents/isolation & purification , Oligochaeta/chemistry , Amino Acid Sequence , Animals , Antimicrobial Cationic Peptides/genetics , Antimicrobial Cationic Peptides/pharmacology , Apoptosis/drug effects , Cell Line , Cell Proliferation/drug effects , Cell Survival/drug effects , Cyclin-Dependent Kinase Inhibitor p27/genetics , Cyclin-Dependent Kinase Inhibitor p27/metabolism , Helminth Proteins/genetics , Helminth Proteins/pharmacology , Humans , Neurogenesis/drug effects , Neurons/cytology , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Oligochaeta/genetics , Oxidopamine/antagonists & inhibitors , Oxidopamine/toxicity , Parkinson Disease/drug therapy , Proteasome Endopeptidase Complex/metabolism , Proteolysis/drug effects
3.
Biochem Biophys Res Commun ; 437(1): 35-40, 2013 Jul 19.
Article in English | MEDLINE | ID: mdl-23791873

ABSTRACT

We recently demonstrated that the antibacterial peptide, CopA3 (a D-type disulfide dimer peptide, LLCIALRKK), inhibits LPS-induced macrophage activation and also has anticancer activity in leukemia cells. Here, we examined whether CopA3 could affect neuronal cell proliferation. We found that CopA3 time-dependently increased cell proliferation by up to 31 ± 2% in human neuroblastoma SH-SY5Y cells, and up to 29 ± 2% in neural stem cells isolated from neonatal mouse brains. In both cell types, CopA3 also significantly inhibited the apoptosis and viability losses caused by 6-hydroxy dopamine (a Parkinson disease-mimicking agent) and okadaic acid (an Alzheimer's disease-mimicking agent). Immunoblotting revealed that the p27Kip1 protein (a negative regulator of cell cycle progression) was markedly degraded in CopA3-treated SH-SY5Y cells. Conversely, an adenovirus expressing p27Kip1 significantly inhibited the antiapoptotic effects of CopA3 against 6-hydroxy dopamine- and okadaic acid-induced apoptosis, and decreased the neurotropic effects of CopA3. These results collectively suggest that CopA3-mediated protein degradation of p27Kip1 may be the main mechanism through which CopA3 exerts neuroprotective and neurotropic effects.


Subject(s)
Antimicrobial Cationic Peptides/pharmacology , Apoptosis/drug effects , Coleoptera/chemistry , Cyclin-Dependent Kinase Inhibitor p27/metabolism , Insect Proteins/pharmacology , Neurons/cytology , Neuroprotective Agents/pharmacology , Peptides/pharmacology , Proteolysis/drug effects , Amino Acid Sequence , Animals , Antimicrobial Cationic Peptides/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Half-Life , Humans , Insect Proteins/chemistry , Mice , Molecular Sequence Data , Neural Stem Cells/cytology , Neural Stem Cells/drug effects , Neural Stem Cells/metabolism , Neuroblastoma/pathology , Neurons/drug effects , Neurons/metabolism , Okadaic Acid/pharmacology , Oxidopamine/pharmacology , Peptides/chemistry
4.
J Microbiol Biotechnol ; 26(4): 693-9, 2016 Apr 28.
Article in English | MEDLINE | ID: mdl-26809801

ABSTRACT

Clostridium difficile toxin A is known to cause deacetylation of tubulin proteins, which blocks microtubule formation and triggers barrier dysfunction in the gut. Based on our previous finding that the Clostridium difficile toxin A-dependent activation of histone deacetylase 6 (HDAC-6) is responsible for tubulin deacetylation and subsequent microtubule disassembly, we herein examined the possible effect of potassium acetate (PA; whose acetyl group prevents the binding of tubulin to HDAC-6) as a competitive/false substrate. Our results revealed that PA inhibited toxin A-induced deacetylation of tubulin and recovered toxin A-induced microtubule disassembly. In addition, PA treatment significantly decreased the production of IL-6 (a marker of inflamed tissue) in the toxin A-induced mouse enteritis model. An in vitro HDAC assay revealed that PA directly inhibited HDAC-6-mediated tubulin deacetylation, indicating that PA acted as a false substrate for HDAC-6. These results collectively indicate that PA treatment inhibits HDAC-6, thereby reducing the cytotoxicity and inflammatory responses caused by C. difficile toxin A.


Subject(s)
Bacterial Toxins/toxicity , Enterotoxins/toxicity , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/metabolism , Inflammation/prevention & control , Potassium Acetate/pharmacology , Tubulin/metabolism , Animals , Colitis/drug therapy , Colon/cytology , Colon/drug effects , Disease Models, Animal , Enteritis/drug therapy , HT29 Cells , Histone Deacetylase 6 , Humans , Inflammation/drug therapy , Interleukin-6/blood , Male , Mice
5.
J Microbiol Biotechnol ; 25(10): 1640-7, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26215270

ABSTRACT

We recently reported that the antimicrobial peptide Lumbricusin (NH2-RNRRWCIDQQA), isolated from the earthworm, increases cell proliferation in neuroblastoma SH-SY5Y cells. Here, we investigated whether Lumbricusin has neurotropic activity in mouse neural stem cells (MNSCs) and a protective effect in a mouse model of Parkinson's disease (PD). In MNSCs isolated from mouse brains, Lumbricusin treatment significantly increased cell proliferation (up to 12%) and reduced the protein expression of p27(Kip1) through proteasomal protein degradation but not transcriptional regulation. Lumbricusin inhibited the 6-OHDA-induced apoptosis of MNSCs, and also showed neuroprotective effects in a mouse PD model, ameliorating the motor impairments seen in the pole, elevated body swing, and rotation tests. These results suggest that the Lumbricusin-induced promotion of neural cell proliferation via p27(Kip1) degradation has a protective effect in an experimental PD model. Thus, the antimicrobial peptide Lumbricusin could possibly be developed as a potential therapeutic agent for the treatment of PD.


Subject(s)
Antimicrobial Cationic Peptides/metabolism , Dopaminergic Neurons/drug effects , Helminth Proteins/metabolism , Motor Disorders/drug therapy , Neuroprotective Agents/metabolism , Parkinson Disease/drug therapy , Parkinson Disease/pathology , Animals , Antimicrobial Cationic Peptides/administration & dosage , Cell Proliferation/drug effects , Cells, Cultured , Disease Models, Animal , Helminth Proteins/administration & dosage , Mice , Neural Stem Cells/drug effects , Neural Stem Cells/physiology , Neuroprotective Agents/administration & dosage , Treatment Outcome
6.
J Microbiol Biotechnol ; 24(5): 696-703, 2014 May.
Article in English | MEDLINE | ID: mdl-24509250

ABSTRACT

Clostridium difficile causes mucosal damage and diarrhea by releasing two exotoxins: toxin A and toxin B. C. difficile colitis is associated with alterations in bowel flora and the failure to mount an effective antibody response. The aim of the current study was to investigate whether antitoxin sera prevent toxin-A-induced apoptosis, cytoskeletal disaggregation, cell detachment, and tight junction loss in cultured colonic epithelial cells. Serum samples were isolated from mice that survived a C. difficile infection following antibiotic treatment, and the antitoxin effects of these samples were investigated in toxin-A-exposed HT29 colonic epithelial cells and a toxin-A-induced animal model of gut inflammation. Unchallenged mice did not produce IgG against toxin A, whereas serum (antiserum) from C. difficile-challenged mice showed significant IgG responses against toxin A. Treatment with the antiserum markedly inhibited mucosal damage and inflammation in the toxin-A-treated mouse model. In contrast to control mouse serum, the antiserum also markedly inhibited toxin-A-induced DNA fragmentation, dephosphorylation of paxillin and Epo receptor (EpoR), deacetylation of tubulin, and upregulation of p21(WAF1/CIP1) and p53. Taken together, these results reveal that the generated antitoxin serum has biotherapeutic effects in preventing various C. difficile toxin-A-induced cellular toxicities.


Subject(s)
Bacterial Toxins/adverse effects , Clostridioides difficile/immunology , Enterocolitis, Pseudomembranous/immunology , Enterotoxins/adverse effects , Immune Sera/immunology , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Animals , Antitoxins/immunology , Apoptosis/drug effects , Apoptosis/immunology , Cell Death/drug effects , Cell Death/immunology , Cell Line , Colitis/chemically induced , Colitis/immunology , Colitis/metabolism , Disease Models, Animal , HT29 Cells , Humans , Immune Sera/pharmacology , Intestinal Mucosa/immunology , Intestinal Mucosa/microbiology , Intestinal Mucosa/pathology , Male , Mice , Signal Transduction , Stress, Physiological
7.
BMB Rep ; 47(9): 494-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24393524

ABSTRACT

NADH:quinone oxidoreductase 1 (NQO1) is known to be involved in the regulation of energy synthesis and metabolism, and the functional studies of NQO1 have largely focused on metabolic disorders. Here, we show for the first time that compared to NQO1-WT mice, NQO1-KO mice exhibited a marked increase of permeability and spontaneous inflammation in the gut. In the DSS-induced colitis model, NQO1-KO mice showed more severe inflammatory responses than NQO1-WT mice. Interestingly, the transcript levels of claudin and occludin, the major tight junction molecules of gut epithelial cells, were significantly decreased in NQO1-KO mice. The colons of NQO1-KO mice also showed high levels of reactive oxygen species (ROS) and histone deacetylase (HDAC) activity, which are known to affect transcriptional regulation. Taken together, these novel findings indicate that NQO1 contributes to the barrier function of gut epithelial cells by regulating the transcription of tight junction molecules.


Subject(s)
Epithelial Cells/enzymology , NAD(P)H Dehydrogenase (Quinone)/metabolism , Tight Junctions/enzymology , Animals , Cell Membrane Permeability , Cells, Cultured , Claudin-1/metabolism , Colitis/chemically induced , Colitis/metabolism , Colitis/pathology , Disease Models, Animal , Down-Regulation , Epithelial Cells/cytology , Epithelial Cells/metabolism , Histone Deacetylases/metabolism , Mice , Mice, Knockout , NAD(P)H Dehydrogenase (Quinone)/deficiency , NAD(P)H Dehydrogenase (Quinone)/genetics , Occludin/metabolism , Reactive Oxygen Species/metabolism , Tight Junctions/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL